Investigating the association between genetically proxied circulating levels of immune checkpoint proteins and cancer survival: protocol for a Mendelian randomisation analysis

Tessa Bate,Richard M Martin,James Yarmolinsky,Philip C Haycock

DOI: https://doi.org/10.1136/bmjopen-2023-075981

IF: 3.006

2024-02-17

BMJ Open

Abstract:Introduction Compared with the traditional drug development pathway, investigating alternative uses for existing drugs (ie, drug repurposing) requires substantially less time, cost and resources. Immune checkpoint inhibitors are licensed for the treatment of certain breast, colorectal, head and neck, lung and melanoma cancers. These drugs target immune checkpoint proteins to reduce the suppression of T cell activation by cancer cells. As T cell suppression is a hallmark of cancer common across anatomical sites, we hypothesise that immune checkpoint inhibitors could be repurposed for the treatment of additional cancers beyond the ones already indicated. Methods and analysis We will use two-sample Mendelian randomisation to investigate the effect of genetically proxied levels of protein targets of two immune checkpoint inhibitors—programmed cell death protein 1 and programmed death ligand 1—on survival of seven cancer types (breast, colorectal, head and neck, lung, melanoma, ovarian and prostate). Summary genetic association data will be obtained from prior genome-wide association studies of circulating protein levels and cancer survival in populations of European ancestry. Various sensitivity analyses will be performed to examine the robustness of findings to potential violations of Mendelian randomisation assumptions, collider bias and the impact of alternative genetic instrument construction strategies. The impact of treatment history and tumour stage on the findings will also be investigated using summary-level and individual-level genetic data where available. Ethics and dissemination No separate ethics approval will be required for these analyses as we will be using data from previously published genome-wide association studies which individually gained ethical approval and participant consent. Results from analyses will be submitted as an open-access peer-reviewed publication and statistical code will be made freely available on the completion of the analysis.

medicine, general & internal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to study the association between genetically - proxied circulating immune checkpoint protein levels and the survival rates of seven cancer types (breast cancer, colorectal cancer, head and neck cancer, lung cancer, melanoma, ovarian cancer and prostate cancer) through Mendelian Randomisation (MR) method. Specifically, the researchers hope to evaluate the impact of the genetically - proxied levels of the protein targets of two specific immune checkpoint inhibitors - programmed cell death protein 1 (PD - 1) and programmed death ligand 1 (PD - L1) on the survival of the above - mentioned cancers through this analysis method.

The main purpose of the study is to explore whether these immune checkpoint inhibitors can be repurposed for the treatment of other types of cancers in addition to the already - approved indications, thereby providing new strategies for cancer treatment. This can not only reduce the time, cost and resource requirements for new drug development, but may also bring hope to cancer patients whose current treatment methods are limited or ineffective.